Systemic Lupus Erythematosus: The Daily PANCE Blueprint
A 27-year-old Black woman presents with four months of fatigue, low-grade fevers, and aching in her hands, wrists, and knees that is worst in the morning. She has noticed that a rash across her cheeks and the bridge of her nose flares after time outdoors, sparing the nasolabial folds. On examination her joints are tender and swollen but not deformed or eroded, and she has painless ulcers on her hard palate. Laboratory studies show hemoglobin 10.1 g/dL, white count 3,100/µL, platelets 96,000/µL, a normal creatinine, and a normal urinalysis. The antinuclear antibody is positive at 1:1280, and anti–double-stranded DNA and anti-Smith antibodies are positive. Complement C3 and C4 are low. Systemic lupus erythematosus is diagnosed. Which of the following should be started and continued long term as the foundation of her treatment?
A. Low-dose prednisone indefinitely
B. Hydroxychloroquine
C. Cyclophosphamide
D. Rituximab
E. Methotrexate
Answer and topic summary
The answer is B. Hydroxychloroquine
Hydroxychloroquine is foundational therapy for essentially every patient with systemic lupus erythematosus, whatever the disease severity, and the 2023 EULAR update is emphatic that it should not be withdrawn unless the patient cannot tolerate it. Dose it at 5 mg/kg/day or less of actual body weight for long-term use. What it buys is not subtle. Hydroxychloroquine reduces flares, spares glucocorticoid, protects against organ damage and thrombosis, and improves survival. It also helps exactly the problems this woman has — the photosensitive rash, the arthritis, the constitutional symptoms. It is slow, taking weeks to months to work, so a short glucocorticoid course is often used as a bridge, and every patient needs a baseline and then annual ophthalmologic screening for retinal toxicity, which is the reason for the weight-based ceiling. The rest of the regimen is layered on top according to what organs are involved. This patient has mucocutaneous, articular, and hematologic disease with a normal urinalysis and creatinine — no nephritis — so hydroxychloroquine plus a short steroid bridge is the right starting point. Sorting the distractors: indefinite prednisone is precisely what modern management tries to avoid; EULAR now caps chronic maintenance at 5 mg/day or less and pushes toward withdrawal, because cumulative steroid, not lupus itself, causes much of the long-term damage these patients accrue. Cyclophosphamide is reserved for severe organ-threatening disease — proliferative lupus nephritis, CNS lupus, alveolar hemorrhage — and its gonadal toxicity makes it a poor choice in a 27-year-old with none of those. Rituximab is an off-label option for refractory disease after first-line agents have failed, not an opening move. And methotrexate is a reasonable steroid-sparing add-on for stubborn lupus arthritis, but it is an adjunct layered onto hydroxychloroquine — never a replacement for it.
View blueprint lesson
Smarty PANCE Content Blueprint Review:
Covered under ⇒ PANCE Blueprint Musculoskeletal ⇒ ⇒
